Trial
NCT02493322
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
EMS
Collaborators
—
Condition
Essential Arterial Hypertension
Intervention
Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg
Why stopped
Decided by Sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-08